DoW Autism Clinical Trial Award

Status

Closed

Agency

Defense · DOD-AMRAA

Notice

HT942526ARPCTA

Type

Grant / cooperative agreement

Value

Total program funding: $3,250,000

Deadline

Oct 22, 2026 · confirm cutoff time in notice

Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

From the official notice

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest. Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical…

Source and next steps

Read the official notice and response instructions

This is a sourced opportunity notice. The summary is an excerpt from the issuing agency; amounts and eligibility are taken from its structured record. Check the full notice, amendments and submission requirements before responding.

Source observed 2026-10-23 Eastern. Browse opportunities